

3. Seino Y, Miyoshi H, Traberg HB, Divyalasya TVS, Nishijima K, Terauchi Y. A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg. *J Diabetes Invest.* 2022 in press


2021


2020


2019


2018


58. Kitao N, Miyoshi H*, Furumoto T, et al. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). *Cardiovasc Diabetol*. 16: 125, 2018


Miya A, Nakamura A, Miyoshi H, Takano Y, Atsumi T. Impact of glucose loading on variations in CD4+ and CD8+ T cells in Japanese participants with or without type 2 diabetes. *Frontiers in Endocrinology* (Lausanne), 9:81, 2018


Oita Y, Miyoshi H*, Ono K, et al. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes · Randomized controlled study·. *Endocrine J.*, 65: 141-150, 2018


2017


2010~2016


115. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan QW, **Miyoshi H**. Mashek DG. The role of lipid droplets in metabolic disease in rodents and humans.


